Brazil CADE reviews Boston Scientific’s acquisition of Penumbra
Boston Scientific and Penumbra argued before the Brazilian competition watchdog that their merger creates overlaps in the markets for peripheral clot-management devices and peripheral vascular-embolization agents, but they said the competitive...To view the full article, register now.
Already a subscriber? Click here to view full article